As part of our series focussing on new registrations in Australia, we have added the second of a two-part series on the use of naltrexone/bupropion as a treatment for obesity.
This publication provides results of the phase 3b LIGHT study which reviewed cardiovascular outcomes in patients taking naltrexone/bupropion. It again provides commentary and recommendations from Dr Bobby Chan, an Endocrinologist working at South Sydney Medical Specialists.
Please login below to download this issue (PDF)